Kornimate/medical-research-clean huggingface dataset:
n-3 polyunsaturated fatty acids prevent postoperative recurrence of crohn's disease

Conditions: Inflammatory Bowel Diseases; Crohn Disease; Polyunsaturated Acid Lipidosis

Summary: crohn's disease (cd) is a chronic recurrent intestinal inflammation involving the whole digestive tract, with high disability rate, high surgical rate and high recurrent rate postoperatively. preventing postoperative recurrence in cd patients is an important clinical problem needed urgent intervention. azathioprine (aza) and infliximab (ifx) effectively prevent postoperative recurrence in cd patients, but the postoperative recurrence rate is still as high as 41%. oral supplement of n-3 polyunsaturated fatty acids (n-3 pufa) owns the advantages of high compliance and low economic cost. we aim to evaluate the effect of routine treatment (aza/ifx) combined with long-term dietary n-3pufa on the prevention and treatment of postoperative recurrence of cd, which help optimize the treatment strategy for the prevention of postoperative recurrence.


Eligibility criteria:
inclusion criteria: 1. cd patients undergoing partial resection，anastomosis or enterostomy. 2. age ≥18 to ≤80 years; 3. have indications of aza or ifx application (according to the consensus of ecco 2016 years); 4. preoperative diagnosis cd, must provide the biopsy pathological record which accords with the cd diagnosis; 5. if the subject is a woman of childbearing age, pregnancy tests must be conducted at baseline to exclude pregnancy, and the trial process must follow the contraceptive advice of this project 6. subjects must be able and willing to provide written informed consent and comply with the requirements of this research program exclusion criteria: 1. patients without indications use of aza or ifx; 2. isolated colon cd patients; 3. patients who can't take long-term oral intervention of n-3pufa; 4. patients diagnosed with short bowel or short bowel syndrome; 5. patients with severe, progressive or uncontrolled kidney, liver, blood or endocrine diseases; 6. postoperative abdominal infection, anastomotic fistula and other complications; 7. there's an infection, such as clostridium difficile toxin or other intestinal pathogens infection, active tuberculosis or intestinal tuberculosis, human immunodeficiency virus (hiv) infection, active hepatitis b or hepatitis c; 8. patients with a history of gastrointestinal dysplasia; patients with 9. tpmt gene mutations or low activity; 10. patients who has already participated in other clinical trial.
study to evaluate efficacy/safety of combination budesonide/indacaterol vs fluticasone/salmeterol in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: to demonstrate the free combination of budesonide and indacaterol is as efficacious as fluticasone and salmeterol in patients with copd


Eligibility criteria:
inclusion criteria: * written informed consent must be obtained before any assessment is performed * outpatients with stable copd groups c and d according to the 2011 gold guidelines. * current or ex-smokers who have a smoking history of at least 10 pack years * patients with a history of at least one exacerbation. * patients able to read and complete exclusion criteria: * use of other investigational drugs within 30 days * patients with a history of hypersensitivity to any of the study drugs * history or current diagnosis of ecg abnormalities * patients with diabetes type i or uncontrolled diabetes type ii including patients with a history of blood glucose levels consistently outside the normal range * patients who have not achieved an acceptable spirometry result at visit 1 * patients with a body mass index (bmi) of more than 40 kg/m2 * patients with lung cancer or a history of lung cancer * patients with a history of malignancy of any organ system * pregnant or nursing (lactating) women * women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment * patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers) * patients that are uncontrolled or unstable on permitted therapy, who in the opinion of the investigator, have clinically significant renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or haematological abnormalities which could interfere with the assessment of the efficacy and safety of the study treatment * patients requiring oxygen therapy for chronic hypoxemia * patients who have had a respiratory tract infection within 6 weeks prior to visit 1 * patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis, bronchiectasis, sarcoidosis, interstitial lung disorder or pulmonary hypertension * patients with a known diagnosis of alpha-1 antitrypsin deficiency. * patients with history of lung surgery * patients who are participating in the active phase of a supervised pulmonary rehabilitation program. * patients with a history of asthma other protocol-defined inclusion/exclusion criteria may apply
clinical impact of parathyroid autofluorescence visualization during thyroid surgery

Conditions: Hypocalcemia

Summary: this before-and-after controlled study study evaluates the clinical impact of parathyroid autofluorescence visualization using near infrared light (nir) during total thyroidectomy (tt). it compares two groups of consecutive patients who underwent tt associated or not to lymph node dissection (lnd) with and without intraoperative use of nir, by the same surgeon.

total thyroidectomy (tt) is responsible for postoperative hypocalcemia in 20-30% of patients, which is definitive in 1-4% of operated patients (1). this complication is mainly due to surgery-induced parathyroid dysfunction, which could be improved by a better intraoperative identification of the parathyroids. intraoperative parathyroid auto-fluorescence visualization (without any dye injection) using near infrared light (nir) is an emerging technique, which allows correct identification of normal parathyroids in almost all cases (2), but the clinical impact of nir is unknown. the main objective of this study is to assess the impact of intraoperative use of nir camera on postoperative hypocalcemia. secondary objectives are to assess the impact of nir on the visualization, autotransplantation and inadvertent resection rates during tt. the investigators compare 2 groups of patients operated by one surgeon during 2 consecutive but distinct periods (before and after the use of nir) with control groups operated by another surgeon during the same periods. this study is observational since there was no predefined protocol nor sample size calculation of study groups prior to data collection.

Eligibility criteria:
inclusion criteria: * all patients who underwent one-stage total thyroidectomy, associated or not to lymph node dissection (tt +/- lnd) exclusion criteria: * combined parathyroid and thyroid disease (including patients with enlarged parathyroids incidentally found during surgery and resected)

Keywords: postoperative hypocalcemia near infrared imaging parathyroid autofluorescence
effect of patient demographics, comorbidities, and medications on severity of nash fibrosis

Conditions: Non-Alcoholic Fatty Liver Disease; Non Alcoholic Steatohepatitis

Summary: few studies have evaluated an extensive list of possible risk factors for nafld for their association with presence and severity of histologic features. we wish to conduct a retrospective study on these possible factors (including demographics, comorbid diseases, and medications) for their association, if any, with severity of histopathologic findings. this study hypothesize that certain risk factors, specifically those contributing to or consisting of metabolic syndrome, will have higher nash fibrosis stages.

non-alcoholic fatty liver disease (nafld) is the most common cause of chronic liver disease in western countries, and is projected to become one of the foremost indications for liver transplantation (2). both nafld and its most severe histopathologic subtype, non-alcoholic steatohepatitis (nash) can progress to cirrhosis and its complications including hepatic malignancy, and are thus an important target for study. it is well-known that several risk factors are associated with the development of nafld, including obesity, type 2 diabetes mellitus, and metabolic syndrome (1), however their association with the presence and severity of histologic features of nafld/nash has not been extensively examined. this study can help determine prognostic indicators for nalfd/nash which can be useful in its prevention and treatment. this is a retrospective chart review and de-identified data analysis. data will be extracted from the patient database from the methodist liver institute from april 2013 - june 2020. patients with confirmed nafld/nash via liver biopsy will be selected and nafld activity score and fibrosis stage will be assessed. data will then be collected on demographics, comorbid diseases, and medications from epic emr system used by methodist health system.

Eligibility criteria:
inclusion criteria: * patients identified to have biopsy-proven nash within april 2013 - june 2020 * minimum age 18, no upper limit of age * patients with complete records exclusion criteria: * age \<18 years * incomplete records * diseases other than nash

Keywords: nash nafld
can b12 and folate levels predict hpv penetration in patients with ascus?

Conditions: ASC-US; Human Papilloma Virus

Summary: non-classified atypical squamous cells (ascus) is the most common abnormal cervical cytology (%39). the risk of cervical intraepithelial neoplasia 2-3 is 5% and the risk of carcinoma is around 0.1% after diagnosis. mostly human papillomavirus (hpv) is responsible for this transition. most of them are transient, but some infections become persistent and can progress into precancer and invasive cancer. in the process of progression to cancer; patients with cell cycle problems are thought to be at risk. in some studies, b12 and folate deficiency, which play a role in dna synthesis and repair, have been shown to induce incorrect binding of uracil to dna, leading to dna breakage and repair disorder. therefore, in this study, it has been aimed that the relation of presence of atypical squamous cells and hpv persistence with folate and vitamin b12 levels which effect on immune system.

participants were divided into two groups according to their smear results; atypical squamous cells of undetermined significance (ascus) (study group: 100 patients) and women who did not have intraepithelial neoplasia as a result of smear (control group: 100 patients). patients who had well preserved sufficient number of squamous epithelial cells, who did not have bleeding, fixation failure, inflammation or atrophy, and had negative cervical cytology smear were considered as control group. hpv test was also requested from the study group. b12 and folate blood levels were compared between the groups.

Eligibility criteria:
inclusion criteria: * female patients aged between 30-65 who were undergoing smear tests with the aim of control * body mass index (bmi) lower than 35 * participants did not have any chronic diseases exclusion criteria: * patients taking b12 and folate supplement due to mix type anemia * patients taking active vitamin b12 and folate-containing vitamin supplements * pregnant women * women with other cervical intraepithelial lesions such as low grade squamous intraepithelial lesion (lgsil), high grade squamous intraepithelial lesion (hgsil) or high grade squamous intraepithelial lesion can not be excluded (asc-h) in smear * patients with cervical cancer diagnosis * patients who were operated due to cervical cancer * patients who had hpv vaccine * patients with a diagnosis that can inhibit b12 and folate absorption in gastro-intestinal tract * vegetarians

Keywords: ascus hpv vitamine b12 folate
photodynamic diagnosis of upper tract urothelial carcinoma using fluorescence endoscopy and oral 5-ala

Conditions: Upper Tract Urothelial Carcinoma

Summary: this study is evaluating whether a medication called 5-aminolevulinic acid (5-ala), approved by the fda for use in brain surgery, can help improve the visibility of upper tract urothelial tumors during surgery. patients undergoing ureteroscopic tumor resection will receive 5-ala prior to surgery, and surgeons will use special blue light to help identify abnormal tissue that might not be seen under standard white light. the goal is to assess whether this technique can enhance tumor detection and removal.

this is a prospective, single-arm feasibility study investigating the use of 5-aminolevulinic acid (5-ala, gleolan) to enhance intraoperative tumor visualization in patients undergoing ureteroscopic resection for suspected upper tract urothelial carcinoma (utuc). 5-ala is an fda-approved oral agent used in glioma surgery to promote fluorescence of malignant tissue under blue light. this study will evaluate whether similar visualization can be achieved in the upper urinary tract to aid in the identification and resection of utuc. up to 10 participants will be enrolled. safety, technical feasibility, and tumor detection outcomes will be measured.

Eligibility criteria:
inclusion criteria: * patients aged 18 or older undergoing diagnostic or therapeutic ureteroscopy for a known or suspected upper tract urothelial tumor * able to provide informed consent * able to comply with study requirements exclusion criteria: * known porphyria or hypersensitivity to porphyrins * pregnant or breastfeeding women * ast or alt \> 2x upper limit of normal within 30 days prior to surgery * participation in another investigational study within 30 days * known allergy or contraindication to 5-ala or its components

Keywords: photodynamic diagnosis 5-ala gleolan ureteroscopy fluorescence endoscopy urothelial cancer blue light kidney cancer urologic oncology minimally invasive surgery
incidence, clinical characteristics and prognosis of patients with st-segment elevation myocardial infarction (stemi) and spontaneous coronary reperfusion in the modern antithrombotic strategy area

Conditions: Coronary Syndrome

Summary: the rapid and complete restoration of coronary flow is a key issue in the management of stemi. primary percutaneous coronary intervention (pci) is the preferred reperfusion strategy associated with antithrombotic drugs. in daily practice, it is not rare that some patients may achieve reopening of the culprit artery without undergoing any mechanical reperfusion therapy, which is called " spontaneous reperfusion ". the latter is associated with improved outcomes in several studies but none of these studies were done in the modern antithrombotic strategy area including new p2y12 inhibitors. the aim of this study is to report the incidence, characteristics and outcomes of consecutive patients with stemi admitted for coronary angiography with angiographic clinical evidence of spontaneous reperfusion in the modern medical antithrombotic strategy associated with primary pci.


Eligibility criteria:
inclusion criteria: * older than 18 years old. * patients with ongoing (within 12 hours after onset of symptoms) stemi admitted for coronary angiography and receiving preloading dose of aspirin, heparin and p2y12 inhibitor exclusion criteria: * patients with thrombolysis treatment before angiography * patients with cardiac arrest without st-segment elevation on ecg after resuscitation * patients with myocardial infarction outside of acute phase (pain lasting more 12 hours) * patients with mental disease * patients not living in france
a study of the safety and efficacy of sp-624 in the treatment of adults with major depressive disorder

Conditions: Major Depressive Disorder

Summary: this is a phase 2 clinical study evaluating the safety and effectiveness of sp-624 as compared to placebo in the treatment of adults with major depressive disorder.


Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent to participate in the study * males and females, aged 18 to 65 years * in generally good physical health * body mass index (bmi) must be between 18 and 40 kg/m2 * females of reproductive potential and males with partners of reproductive potential must agree to remain abstinent or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of study drug * subjects must meet criteria for moderate to severe major depressive disorder, as confirmed by the mini international neuropsychiatric interview (mini) * willing and able to comply with the study design schedule and other requirements exclusion criteria: * female who is pregnant, breastfeeding, or less than six months postpartum at screening * history or presence of any clinically significant medical condition, disease, or surgical history that could jeopardize the safety of the subject or validity of the study data, or interfere with the absorption, distribution, metabolism, or excretion of the study drug * failure to discontinue all psychoactive medications or psychoactive supplements including antidepressants and mood stabilizers, within a time period prior to baseline corresponding to at least five half-lives of the medication in question * presence of a clinically significant abnormality on physical examination or electrocardiogram (ecg), including a corrected qt interval using fridericia's formula (qtcf) \>450 msec for males and \>470 msec for females * presence of uncontrolled hypertension, defined as consistent systolic blood pressure (sbp) \>160 mmhg or consistent diastolic blood pressure (dbp) \>95 mmhg despite present therapy * screening laboratory value(s) outside the laboratory reference range that are considered to be clinically significant by the investigator (clinical chemistry, hematology, coagulation, and urinalysis) * screening liver function tests (alt, ast, alkaline phosphatase) \> 2x the upper limit of normal * subjects who, in the opinion of the investigator, are not suitable candidates for the study
efficacy of adding interpersonal and emotional processing therapy techniques to cognitive behavioral therapy to treat generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: this study will test a version of cognitive behavioral therapy for generalized anxiety disorders that incorporates interpersonal and emotional processing techniques.

generalized anxiety disorder (gad) is characterized by chronic worry that interrupts normal functioning. some research has shown cognitive behavioral therapy (cbt) to be an effective treatment for gad, but only half of people treated with cbt for gad experience treatment benefits long-term. standard cbt for gad may lose effectiveness over time because it does not address interpersonal and emotional processing problems. this study will determine the efficacy of a version of cbt with additional therapeutic techniques for addressing interpersonal interactions and emotional processing among adults with gad. participation in this study will include 14 weeks of treatment and 2 years of follow-up visits. all participants will receive 14 weekly, 2-hour, individual therapy sessions and one maintenance session scheduled after completing treatment. during the first hour of each session, all participants will receive standard cbt. participants will be randomly assigned to receive one of two therapies during the second hour: training in interpersonal and emotional processing techniques or listening therapy. participants may continue taking their current medications if they maintain a fixed dosage and keep a daily dairy of medication use, starting 2 weeks before study entry and lasting throughout treatment. in-depth study assessments will take place at baseline and after completing the 14 weeks of therapy. assessments will include clinical interviews, self-report questionnaires, and a physiological measurement session. questions will pertain to anxiety symptoms, self-perceptions, emotional experience, and perceptions of the world. the physiological measurement session will involve recording bodily reactions, including brain waves, heart rate, eye movement, and breathing, while performing simple perceptual tasks. brief psychological assessments will also follow each therapy session. follow-up assessments conducted 6, 12, and 24 months after completing treatment will involve interviews and questionnaires as well as recording a week's worth of medication diaries.

Eligibility criteria:
inclusion criteria: * principal diagnosis of generalized anxiety disorder (gad), as defined by the dsm-iv and agreed on by two diagnostic interviewers * clinician's severity rating for gad of 4 (moderate) or greater exclusion criteria: * concurrent psychosocial therapy or past adequate dosage of cbt * any medical contributions to anxiety * current substance abuse, psychosis, or organic brain syndrome

Keywords: cbt gad interpersonal therapy emotion-focused therapy
a multicomponent clinic-based intervention to promote covid-19 vaccine intention and uptake among diverse youth and adolescents

Conditions: COVID-19 Vaccination

Summary: the goal of this study is to refine and test confidence, a multi-component clinic-based intervention in pediatric or family practice clinical settings. using a randomized control trial design, the investigators will assess preliminary effectiveness of the intervention to increase covid-19 vaccine intention among parents of under-vaccinated children ages 5 to 17. participating clinics will receive a brief intervention consisting of: (1) webinar training focused on communication with vaccine-hesitant parents, (2) parent-facing educational materials about covid-19 vaccination, (3) support to create a personalized, poster campaign featuring providers. clinics in the control condition will receive the intervention approximately 12 months after the clinics in the intervention condition.


Eligibility criteria:
practice site inclusion criteria * pediatric or family practice clinic that serves pediatric population (ages 5 to 17) * affiliated with umass memorial health care and/or baystate health * serve a patient population that is at least 30% racial/ethnic minority group members. inclusion criteria for parents: the following inclusion criteria will be applied to parents (on behalf of their children): * parent/guardian (referred to as parents in this proposal) of child between ages 5 and 17 * able to read and write in english, spanish, portuguese or vietnamese, which are the predominant languages in the target communities * parent of patient at participating clinical site/child received non-urgent care visit during study period * child not up-to-date for covid-19 per current cdc guidelines at the time of enrollment. exclusion criteria for parents: °parent under age of 18

Keywords: vaccination hesitancy